Cite

HARVARD Citation

    Rusakiewicz, S. et al. (2017). NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. p. . [Online]. 
  
Back to record